We have isolated a novel cDNA encoding a peptide with 86% sequence homology to hSNF2L protein, a previously isolated human homologue of Drosophila ISWI. This gene, designated SMARCA5, contained an open reading frame of 3,156 nucleotides encoding a 1,052 amino-acid peptide (hSNF2H). As this product also revealed a significant (73%) identity in amino acid sequence to ISWI, a key component of chromatin-remodeling factors in Drosophila, hSNF2H may be another human homologue of this protein and, as such, could be involved in chromatin remodeling in humans. An ATPase domain characteristic of the SWI2/SNF2 family of proteins was highly conserved in ISWI, hSNF2L, and hSNF2H. Northern-blot analysis demonstrated ubiquitous expression of 5.1-kb and 4.1-kb transcripts of the hSNF2H gene. This gene was mapped by FISH to chromosome bands 4q31.1→q31.2.

1.
Buetow KH, Murray JC, Israel JL, London WT, Smith M, Kew M, Blanquet V, Brechot C: Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Proc natl Acad Sci, USA 86:8852–8856 (1989).
2.
Eisen JA, Sweder KS, Hanawalt PC: Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions. Nucl Acids Res 23:2715–2723 (1995).
3.
Elfring LK, Deuring R, McCallum CM, Peterson CL, Tamkun JW: Identification and characterization of Drosophila relatives of the yeast transcriptional activator SNF2/SWI2. Mol Cell Biol 14:2225–2234 (1994).
4.
Ito T, Bulger M, Pazin MJ, Kobayashi R, Kadonaga JT: ACF, an ISWI-containing and ATP-utilizing chromatin assembly and remodeling factor. Cell 90:145–155 (1997).
5.
Lichter P, Ledbetter SA, Ledbetter DH, Ward DC: Fluorescence in situ hybridization with Alu and L1 polymerase chain reaction probes for rapid characterization of human chromosomes in hybrid cell lines. Proc natl Acad Sci, USA 87:6634–6638 (1990).
6.
Okabe I, Bailey LC, Attree O, Srinivasan S, Perkel JM, Laurent BC, Carlson M, Nelson DL, Nussbaum RL: Cloning of human and bovine homologs of SNF2/SWI2: a global activator of transcription in yeast S. cerevisiae. Nucl Acids Res 20:4649–4655 (1992).
7.
Rasio D, Murakumo Y, Robbins D, Roth T, Silver A, Negrini M, Schmidt C, Burczak J, Fishel R, Croce CM: Characterization of the human homologue of RAD54: a gene located on chromosome 1p32 at a region of high loss of heterozygosity in breast tumors. Cancer Res 57:2378–2383 (1997).
8.
Takahashi E, Hori T, O’Connell P, Leppert M, White R: R-banding and nonisotopic in situ hybridization: precise localization of the human type II collagen gene (COL2A1). Hum Genet 86:14–16 (1990).
9.
Takahashi E, Yamauchi M, Tsuji H, Hitomi A, Meuth M, Hori T: Chromosome mapping of the human cytidine-5′-triphosphate synthetase (CTPS) gene to band 1p34.1→p34.3 by fluorescence in situ hybridization. Hum Genet 88:119–121 (1991).
10.
Tsukiyama T, Daniel C, Tamkun J, Wu C: ISWI, a member of the SWI2/SNF2 ATPase family, encodes the 140-kDa subunit of the nucleosome remodeling factor. Cell 83:1021–1026 (1995).
11.
Tsukiyama T, Wu C: Purification and properties of an ATP-dependent nucleosome remodeling factor. Cell 83:1011–1020 (1995).
12.
van-der-Horst GT, van-Steeg H, Berg RJ, van-Gool AJ, de-Wit J, Weeda G, Morreau H, Beems RB, van-Kreijl CF, de-Gruijl FR, Bootsma D, Hoeijmakers JH: Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition. Cell 89:425–435 (1997).
13.
Varga-Weisz PD, Wilm M, Bonte E, Dumas K, Mann M, Becker PB: Chromatin-remodeling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature 388:598–602 (1997).
14.
Wu RS, Panusz HT, Hatch CL, Bonner WM: Histones and their modifications. Crc Crit Rev Biochem 20:201–263 (1986).
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.